Literature DB >> 10596998

The heparin-protamine interaction. A review.

J A Carr1, N Silverman.   

Abstract

The heparin-protamine interaction is a topic of intense scrutiny due to its mandatory use during cardiopulmonary bypass. It can be estimated that over 2,000,000 patients are exposed to the heparin-protamine interaction each year. From clinical and experimental observation it is known that protamine neutralization of heparin causes increased pulmonary artery pressures and decreased systolic and diastolic blood pressure, myocardial oxygen consumption, cardiac output, heart rate, and systemic vascular resistance. These multiple cardiovascular effects are mediated via complement activation, histamine release, thromboxane and nitric oxide production, and antibody formation. This article reviews the current understanding of the heparin-protamine interaction from the world's literature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596998

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  26 in total

1.  A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.

Authors:  Charlene M Blake; Haichen Wang; Daniel T Laskowitz; Bruce A Sullenger
Journal:  Oligonucleotides       Date:  2010-12-13

Review 2.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

3.  In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.

Authors:  Aaron D Baldwin; Karyn G Robinson; Jaimee L Militar; Christopher D Derby; Kristi L Kiick; Robert E Akins
Journal:  J Biomed Mater Res A       Date:  2012-05-21       Impact factor: 4.396

4.  Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

Authors:  Kristin M Bompiani; Jens L Lohrmann; George A Pitoc; James W Frederiksen; George B Mackensen; Bruce A Sullenger
Journal:  Chem Biol       Date:  2014-07-24

5.  Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.

Authors:  Ming Bai; Meilan Zhou; Lijie He; Feng Ma; Yangping Li; Yan Yu; Pengbo Wang; Li Li; Rui Jing; Lijuan Zhao; Shiren Sun
Journal:  Intensive Care Med       Date:  2015-12       Impact factor: 17.440

6.  Challenges in Perioperative Animal Care for Orthotopic Implantation of Tissue-Engineered Pulmonary Valves in the Ovine Model.

Authors:  Hussam Al Hussein; Hamida Al Hussein; Carmen Sircuta; Ovidiu S Cotoi; Ionela Movileanu; Dan Nistor; Bogdan Cordos; Radu Deac; Horatiu Suciu; Klara Brinzaniuc; Dan T Simionescu; Marius M Harpa
Journal:  Tissue Eng Regen Med       Date:  2020-08-29       Impact factor: 4.169

Review 7.  Reversal of anticoagulant effects in patients with intracerebral hemorrhage.

Authors:  Sean Yates; Ravi Sarode
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

8.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.

Authors:  L M Lee; L C Chang; S Wrobleski; T W Wakefield; V C Yang
Journal:  AAPS PharmSci       Date:  2001

Review 9.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

10.  Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions.

Authors:  Gabriele Pesarini; Sara Ariotti; Flavio Ribichini
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.